EKDH.F Stock Overview
Engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in Europe, the Middle East, the Americas, Asia, Africa, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
EKF Diagnostics Holdings plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.36 |
| 52 Week High | UK£0.40 |
| 52 Week Low | UK£0.36 |
| Beta | 0.57 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | -1.14% |
| Change since IPO | 18.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| EKDH.F | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | -5.7% | -4.6% |
| 1Y | n/a | 3.7% | 8.8% |
Return vs Industry: Insufficient data to determine how EKDH.F performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how EKDH.F performed against the US Market.
Price Volatility
| EKDH.F volatility | |
|---|---|
| EKDH.F Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: EKDH.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine EKDH.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 309 | n/a | www.ekfdiagnostics.com |
EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in Europe, the Middle East, the Americas, Asia, Africa, and internationally. It offers DiaSpect Tm hand-held hemoglobin analyzer; Hemo Control, a hemoglobin and hematocrit analyzer; Ultracrit, a hematocrit device; DiaSpect Hemoglobin T analyzer; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. The company also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Clinic; Quo-Lab A1c, a desktop point-of-care analyzer for measuring glycated hemoglobin; Quo-Test A1c for the monitoring and management of diabetes; and STAT-Site M Beta-hydroxybutyrate analyzer.
EKF Diagnostics Holdings plc Fundamentals Summary
| EKDH.F fundamental statistics | |
|---|---|
| Market cap | US$181.09m |
| Earnings (TTM) | US$6.24m |
| Revenue (TTM) | US$66.57m |
29.0x
P/E Ratio2.7x
P/S RatioIs EKDH.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EKDH.F income statement (TTM) | |
|---|---|
| Revenue | UK£50.95m |
| Cost of Revenue | UK£26.47m |
| Gross Profit | UK£24.48m |
| Other Expenses | UK£19.71m |
| Earnings | UK£4.78m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.011 |
| Gross Margin | 48.05% |
| Net Profit Margin | 9.37% |
| Debt/Equity Ratio | 0% |
How did EKDH.F perform over the long term?
See historical performance and comparisonDividends
3.9%
Current Dividend Yield114%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/10/13 05:58 |
| End of Day Share Price | 2024/07/16 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
EKF Diagnostics Holdings plc is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Julie Simmonds | Canaccord Genuity |
| Jens Lindqvist | Investec Bank plc (UK) |
| Julie Simmonds | Panmure Liberum |